Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
*Both authors (Husni, Solomon) contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…Abstract Number: 563 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Cognitive Impairment in Korean Adults with Rheumatoid Arthritis
Background/Purpose: For persons with chronic diseases such as rheumatoid arthritis (RA), intact cognitive function is crucial for performing main daily activities and adhering to self-management…Abstract Number: 1464 • 2016 ACR/ARHP Annual Meeting
Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age
Background/Purpose: Rheumatoid Arthritis (RA) is associated with a greater cardiovascular mortality than the general population of the same age and gender. Cardiovascular events prediction scales,…Abstract Number: 1494 • 2016 ACR/ARHP Annual Meeting
Myocardial Structure, Function, and Fibrosis in Patients with Rheumatoid Arthritis and Matched Control Subjects
Background/Purpose: The prevalence of heart failure is increased 2-fold in RA; this is not explained by ischemic heart disease or other risk factors for heart…Abstract Number: 2172 • 2016 ACR/ARHP Annual Meeting
Impact of Biologic and Non-Biologic Treatment on the Incidence of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Background/Purpose: Studies have suggested that the chronic inflammatory nature of rheumatic conditions (rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) as well as psoriasis (PsO) may…Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions. However, we previously found that high blood…Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…Abstract Number: 1467 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease
Background/Purpose: Measures of arterial health may be useful in assessing the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA). The…Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…Abstract Number: 2174 • 2016 ACR/ARHP Annual Meeting
Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: The cause of the increased cardiovascular risk in inflammatory rheumatic diseases (IRDs) is still unclear. Intriguingly, selenium-deficiency, which might be caused by poor diet or…Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 38
- Next Page »